Abstract
Oral L-arginine therapy reverses endothelial dysfunction and attenuates high blood pressure in hypertensive cardiac transplant recipients. L-arginine corrects derangements in the vascular endothelial nitric oxide (NO)-dependent signaling pathway. Our data support the concept that cardiac transplant recipients use excess endogenous NO from L-arginine supplementation to buffer increased vascular oxidant stress.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Adolescent
-
Adult
-
Arginine / administration & dosage
-
Arginine / pharmacology*
-
Child
-
Coronary Vessels / drug effects*
-
Endothelium, Vascular / drug effects*
-
Endothelium, Vascular / pathology
-
Female
-
Heart Transplantation*
-
Humans
-
Hypertension / drug therapy*
-
Hypertension / etiology
-
Male
-
Oxidative Stress*